Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 231

1.

18F-FDG PET/CT superscan in prostate cancer.

Bailly M, Besse H, Kerdraon R, Metrard G, Gauvain S.

Clin Nucl Med. 2014 Oct;39(10):912-4. doi: 10.1097/RLU.0000000000000376.

PMID:
24566401
2.

Comparison of bone scintigraphy and 18F-FDG PET-CT in a prostate cancer patient with osteolytic bone metastases.

Ozcan Kara P, Kara T, Kara Gedik G, Sari O, Sahin O.

Rev Esp Med Nucl. 2011 Mar-Apr;30(2):94-6. doi: 10.1016/j.remn.2010.10.008.

3.

The role of 18F-flourocholine PET/CT in biochemically relapsed prostate cancer: a case of osteolytic prostate metastasis.

Tabrizipour AI, Dunne M.

Clin Nucl Med. 2015 May;40(5):e285-6. doi: 10.1097/RLU.0000000000000681.

PMID:
25608148
4.

Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer.

Nuñez R, Macapinlac HA, Yeung HW, Akhurst T, Cai S, Osman I, Gonen M, Riedel E, Scher HI, Larson SM.

J Nucl Med. 2002 Jan;43(1):46-55.

5.
6.

Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases.

Iagaru A, Mittra E, Dick DW, Gambhir SS.

Mol Imaging Biol. 2012 Apr;14(2):252-9. doi: 10.1007/s11307-011-0486-2.

PMID:
21479710
7.

Asymptomatic Solitary Metastasis to the Testis From Prostate Carcinoma Detected by FDG PET/CT.

Hsieh TC, Lin CC, Kao CH, Wu YC, Sun SS.

Clin Nucl Med. 2016 Jan;41(1):86-7. doi: 10.1097/RLU.0000000000001004.

PMID:
26402135
8.

Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma.

Mosavi F, Johansson S, Sandberg DT, Turesson I, Sörensen J, Ahlström H.

AJR Am J Roentgenol. 2012 Nov;199(5):1114-20. doi: 10.2214/AJR.11.8351.

PMID:
23096187
9.

The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and 99mTc-MDP bone scan.

Damle NA, Bal C, Bandopadhyaya GP, Kumar L, Kumar P, Malhotra A, Lata S.

Jpn J Radiol. 2013 Apr;31(4):262-9. doi: 10.1007/s11604-013-0179-7.

PMID:
23377765
10.

Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography.

Ak I, Sivrikoz MC, Entok E, Vardareli E.

Eur J Cardiothorac Surg. 2010 Apr;37(4):792-6. doi: 10.1016/j.ejcts.2009.11.011.

PMID:
20015657
11.

A Case of Massive Bone Metastases From Lung Cancer Detected Only by 18F-FDG PET/CT.

Satoh Y, Koizumi K, Nambu A, Araki T.

Clin Nucl Med. 2015 Aug;40(8):e411-4. doi: 10.1097/RLU.0000000000000836.

PMID:
26018679
12.

F-18 FDG PET/CT imaging in small cell prostate cancer.

de Carvalho Flamini R, Yamaga L, Mello ME, Wagner J, Livorsi da Cunha M, Osawa A, Campos GC, de Gusmão Funari MB.

Clin Nucl Med. 2010 Jun;35(6):452-3. doi: 10.1097/RLU.0b013e3181db4ce9. No abstract available.

PMID:
20479600
13.

Combined 18F-fluorocholine and 18F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer.

Kjölhede H, Ahlgren G, Almquist H, Liedberg F, Lyttkens K, Ohlsson T, Bratt O.

BJU Int. 2012 Nov;110(10):1501-6. doi: 10.1111/j.1464-410X.2012.11123.x.

14.

[PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer].

García JR, Soler M, Blanch MA, Ramírez I, Riera E, Lozano P, Pérez X, Delgado E, Carrio I, Lomeña F.

Rev Esp Med Nucl. 2009 May-Jun;28(3):95-100. Spanish.

15.

F-18 FDG PET superscan.

Su HY, Liu RS, Liao SQ, Wang SJ.

Clin Nucl Med. 2006 Jan;31(1):28-9. No abstract available.

PMID:
16374120
16.

Positron emission tomography and bone metastases.

Fogelman I, Cook G, Israel O, Van der Wall H.

Semin Nucl Med. 2005 Apr;35(2):135-42. Review.

PMID:
15765376
17.

Evaluation of primary prostate cancer using 11C-methionine-PET/CT and 18F-FDG-PET/CT.

Shiiba M, Ishihara K, Kimura G, Kuwako T, Yoshihara H, Sato H, Kondo Y, Tsuchiya S, Kumita S.

Ann Nucl Med. 2012 Feb;26(2):138-45. doi: 10.1007/s12149-011-0551-6. Erratum in: Ann Nucl Med. 2012 Feb;26(2):146. Yoshihara, Naohisa [corrected to Yoshihara, Hisashi].

PMID:
22069194
18.

Evaluation of bone metastases from breast cancer by bone scintigraphy and positron emission tomography/computed tomography imaging.

Pires AO, Borges US, Lopes-Costa PV, Gebrim LH, da Silva BB.

Eur J Obstet Gynecol Reprod Biol. 2014 Sep;180:138-41. doi: 10.1016/j.ejogrb.2014.06.021.

PMID:
25037283
19.

Use of FDG PET-CT in prostate lesion diagnosis.

[No authors listed]

Radiol Technol. 2014 May-Jun;85(5):546M-547M. No abstract available.

PMID:
24806072
20.

Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival.

Vargas HA, Wassberg C, Fox JJ, Wibmer A, Goldman DA, Kuk D, Gonen M, Larson SM, Morris MJ, Scher HI, Hricak H.

Radiology. 2014 Apr;271(1):220-9. doi: 10.1148/radiol.13130625.

Items per page

Supplemental Content

Support Center